Design and rationale of the COMPARE-ACUTE trial: Fractional flow reserve–guided primary multivessel percutaneous coronary intervention to improve guideline indexed actual standard of care for treatment of ST-elevation myocardial infarction in patients with multivessel coronary disease

American Heart Journal

Volumn 186, Issue , 2017, Pages 21-28

  Smits, Pieter C ^a   Assaf, Amira ^a   Richardt, Gert ^b   Omerovic, Elmir ^c   Abdel Wahab, Mohamed ^b   Neumann, Franz Joseph ^d  

^a Maasstad Hospital   (Netherlands)

^b Herzzentrum Segeberger Kliniken   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FRACTIONAL FLOW RESERVE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STUDY DESIGN; ADOLESCENT; CLINICAL TRIAL; COMPLICATION; HEALTH CARE QUALITY; MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; PROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; STANDARD OF CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85009471184     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.12.016     Document Type: Article

References (24)

1. 1. Corpus, R.A., House, J.A., Marso, S.P., et al. Multivessel percutaneous coronary intervention in patients with multivessel disease and acute myocardial infarction. Am Heart J 148 (2004), 493–500.
2. 2. Hanratty, C.G., Koyama, Y., Rasmussen, H.H., et al. Exaggeration of nonculprit stenosis severity during acute myocardial infarction: implications for immediate multivessel revascularization. J Am Coll Cardiol 40 (2002), 911–916.
3. 3. Janardhanan, R., Kenchaiah, S., Velazquez, E.J., et al. Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Am Heart J 152 (2006), 183–189.
4. 4. Kedhi, E., Joesoef, K.S., McFadden, E., et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375 (2010), 201–209.
5. 5. Stone, G.W., Rizvi, A., Newman, W., et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362 (2010), 1663–1674.
6. 6. Montalescot, G., Wiviott, S.D., Braunwald, E., et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009), 723–731.
7. 7. Khattab, A.A., Abdel-Wahab, M., Rother, C., et al. Multi-vessel stenting during primary percutaneous coronary intervention for acute myocardial infarction. A single-center experience. Clin Res Cardiol 97 (2008), 32–38.
8. 8. Hannan, E.L., Samadashvili, Z., Walford, G., et al. Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease. JACC Cardiovasc Interv 3 (2010), 22–31.
9. 9. Vlaar, P.J., Mahmoud, K.D., Holmes, D.R. Jr., et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 58 (2011), 692–703.
10. 10. Kornowski, R., Mehran, R., Dangas, G., et al. Prognostic impact of staged versus “one-time” multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 58 (2011), 704–711.
11. 11. Wald, D.S., Morris, J.K., Wald, N.J., et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 369 (2013), 1115–1123.
12. 12. Gershlick, A.H., Khan, J.N., Kelly, D.J., et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 65 (2015), 963–972.
13. 13. Engstrøm, T., Kelbæk, H., Helqvist, S., et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet 386 (2015), 665–671.
14. 14. Hlinomaz, O., Groch, L., Poloková, K., et al. Multivessel coronary disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus conservative strategy. PRAGUE-13 trial. Kardiol Rev Int Med 17:3 (2015), 214–220.
15. 15. Windecker, S., Kolh, P., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 35 (2014), 2541–2619.
16. 16. Steg, P.G., James, S.K., Atar, D., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
17. 17. Patel, M.R., Dehmer, G.J., Hirshfeld, J.W., et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 53 (2009), 530–553.
18. 18. Kolh, P., Windecker, S., Alfonso, F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 46 (2014), 517–592.
19. 19. Pijls, N.H., De Bruyne, B., Peels, K., et al. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med 334 (1996), 1703–1708.
20. 20. Kern, M.J., Lerman, A., Bech, J.W., et al. Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: a scientific statement from the American Heart Association Committee on Diagnostic and Interventional Cardiac Catheterization, Council on Clinical Cardiology. Circulation 114 (2006), 1321–1341.
21. 21. Tonino, P.A., De Bruyne, B., Pijls, N.H., et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 360 (2009), 213–224.
22. 22. Ntalianis, A., Sels, J.W., Davidavicius, G., et al. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv 3 (2010), 1274–1281.
23. 23. Tonino, P.A., Fearon, W.F., De Bruyne, B., et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol 55 (2010), 2816–2821.
24. 24. Toth, G.G., Kala, P., Lansky, A., Baumbach, A., Will this trial change my practice? PRAMI—treatment of bystander coronary artery lesions in patients undergoing primary PCI for acute STEMI. EuroIntervention 10 (2014), 411–412.